Abstracts Archive - Page 66 of 2425 - ACR Meeting Abstracts

Abstract Number: 0362 • ACR Convergence 2024
Development of a Theory-based Digital Messaging Program to Reduce Fatigue in Systemic Lupus Erythematosus
Anna Deck¹, Paula Caras², Kiran Singh³, Monique Gore-Massy⁴, Faye Chiu⁵, Sara Folta⁶ and Shanthini Kasturi³, ¹Tufts University School of Medicine, Portland, ME, ²Tufts University School of Medicine, Boston, MA, ³Tufts Medical Center, Boston, MA, ⁴Lupus Foundation of America, New Jersey, ⁵N/A, New York City, NY, ⁶Tufts University/Tufts University Friedman School of Nutrition, Boston, MA
Background/Purpose: Fatigue is the single most prevalent symptom of systemic lupus erythematous (SLE), affecting 80-90% of patients, and is often refractory to pharmacologic therapy. Non-pharmacologic…
Abstract Number: 0332 • ACR Convergence 2024
Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort
Sangmee Bae¹, Daniela Macrovic², Auguestine Chung², Jessica Channick², Andrea Oh¹, Jennifer Wang¹, Ani Shahbazian², Tiffany De Leon², Yuna Lee², Grace Kim², Donald Tashkin², Jonathan Goldin² and christina Charles-Schoeman³, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Medical Center, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in idiopathic inflammatory myopathies (IIM), and high-resolution computed tomography (HRCT) is a key modality…
Abstract Number: 0284 • ACR Convergence 2024
Identification of Calcium Pyrophosphate Deposition Using Ultrasonography in Patients with a Suspected Diagnosis of Seronegative Rheumatoid Arthritis
Joanna Potera¹, Angelo Gaffo², Alvin Day³, Mariana Urquiaga² and Amanda Alexander⁴, ¹University of Alabama at Birmingham, Irondale, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Dept. of Veterans Affairs, Lexington, SC, ⁴University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Calcium pyrophosphate deposition disease is a common condition that can cause chronic polyarticular inflammatory joint disease, which sometimes resembles rheumatoid arthritis. Misdiagnosis is especially…
Abstract Number: 0355 • ACR Convergence 2024
Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
Vibeke Strand¹, Puja Khanna², Alan Kivitz³, Nana Kragh⁴, Aletta Falk⁵, Rehan Azeem⁶, Hugues Santin-Janin⁷ and Herbert Baraf⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of Michigan, Ann Arbor, MI, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Sobi, Stockholm, Sweden, ⁶Sobi Inc., Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Center for Rheumatology and Bone Research, Wheaton, MD
Background/Purpose: Patients (pts) with gout have impaired health-related quality of life (HRQoL) relating to acute or chronic inflammation from elevated serum uric acid (sUA) levels.…
Abstract Number: 0391 • ACR Convergence 2024
Using Machine Learning to Predict Inactive Disease in Juvenile Idiopathic Arthritis
Mei-Sing Ong¹, Marc Natter², Laura Schanberg³ and Yukiko Kimura⁴, and CARRA Registry Investigators, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, DURHAM, NC, ⁴Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Optimizing treatment of JIA continues to be a challenge. Biologic DMARD (bDMARD) therapies have significantly improved outcomes but is costly, may be more difficult…
Abstract Number: 0313 • ACR Convergence 2024
Cardiac Sarcoidosis Is Associated with a High Mortality: Retrospective Analysis of a Cohort at Mayo Clinic Florida
Sehreen Mumtaz¹, Jayesh Valecha², Andy Abril³, Florentina Berianu³, Benjamin Wang⁴, Ronald Butendieck⁴, anushka Irani², carolyn mead harvey² and Vikas Majithia², ¹Mayo Clinic, Florida, Jacksonville, FL, ²Mayo Clinic Florida, Jacksonville, FL, ³Mayo Clinic, Ponte Vedra Beach, FL, ⁴Mayo Clinic, Jacksonville, FL
Background/Purpose: Sarcoidosis, characterized by non-necrotizing granulomatous inflammation, is a multisystem disease with an unpredictable disease spectrum. An estimated 5% of sarcoidosis patients have clinically evident…
Abstract Number: 0269 • ACR Convergence 2024
Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease
Yiling Zhang¹, Sara Tedeschi², Abhishek Abhishek³, Owen Hensey⁴, David Grossberg⁵, Ken Cai⁶, Beverley Shea⁷, Jasvinder Singh⁸, Robin Christensen⁹, Teodora Serban¹⁰, Edoardo Cipolletta¹¹, Konstantinos Parperis¹², César Díaz¹³, Geraldine McCarthy¹⁴, Fabio Becce¹⁵, Tamer A Gheita¹⁶, Silvia Sirotti¹⁷, Sara Nysom Christiansen¹⁸, Luis Coronel Tarancon¹⁹, Lisa Stamp²⁰, Yousra H Abdel-Fattah²¹, Tristan Pascart²², Georgios Filippou¹⁷, Lih En Hong²³, John FitzGerald²⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Brigham and Women's Hospital, Boston, MA, ³University of Nottingham, Nottingham, United Kingdom, ⁴OMERACT patient research partner, Dublin, Ireland, ⁵OMERACT patient research partner, Maryland, ⁶Westmead Hospital, Sydney, New South Wales, Australia, ⁷Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁸Baylor College of Medicine, Birmingham, AL, ⁹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹⁰Ospedale La Colletta, Bucharest, Romania, ¹¹Polytechnic University of Marche, Ancona, Italy, ¹²University of Cyprus Medical School, Nicosia, Cyprus, ¹³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁴Mater Misericordiae University Hospital, Dublin, Ireland, ¹⁵Lausanne University Hospital (CHUV), Lausanne, Switzerland, ¹⁶Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁷IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ¹⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, ¹⁹Image and Technics Unit, Department of Rheumatology. Hospital Universitari Vall d’Hebron, Barcelona, Spain, ²⁰University of Otago, Christchurch, Christchurch, New Zealand, ²¹Alexandria University, Alexandria, Egypt, ²²Lille Catholic University, Lille, France, ²³Royal Adelaide Hospital, Unley Park, South Australia, Australia, ²⁴UCLA, Los Angeles, CA
Background/Purpose: To agree on important domains for the Outcome Measures in Rheumatology (OMERACT) core domain set for long-term studies of calcium pyrophosphate deposition (CPPD) disease.Methods:…
Abstract Number: 0337 • ACR Convergence 2024
Characterization of Statin Induced Myopathy in the Hospital Setting
Olivia Yang¹, KUMAR VENKAT², Jeffery Durbin³ and Scott Kubomoto¹, ¹Riverside Community Hospital, Riverside, CA, ²Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, ³HCA Healthcare Physicians Services Group, Brentwood, TN
Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…
Abstract Number: 0373 • ACR Convergence 2024
Enhancing Lupus Patient Education and Support at Kings County Hospital
Dmytro Gatsak¹, Jayashree Gandhi¹, Aleksander Feoktistov², Eugeniya Golub³ and Michael Trevisonno⁴, ¹Kings County Hospital/ SUNY Downstate Medical Center, Brooklyn, NY, ²Kings County Hospital Center/ H+H NYC, Brooklyn, NY, ³Kings County Hospital/ SUNY Downstate Medical Center, Staten Island, NY, ⁴State University of New York Downstate Medical Center, Brooklyn, NY
Background/Purpose: Kings County Hospital, located in Brooklyn, New York, sees an estimated 243 patients with Systemic Lupus Erythematosus (SLE) annually. The patient demographic is predominantly…
Abstract Number: 0303 • ACR Convergence 2024
Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Laura K. Ferris¹, Jerry Bagel², Yu-Huei Huang³, Andrew E. Pink⁴, Stephen K. Tyring⁵, Georgios Kokolakis⁶, Amy M. DeLozier⁷, Daniel Kakaley⁸, Shu Li⁹, Yaung-Kaung Shen¹⁰, Takayuki Ota⁷ and Robert Bissonnette¹¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Psoriasis Treatment Center of Central NJ, East Windsor, NJ, ³Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), ⁴NHS Foundation Trust Great Maze Pond, London, United Kingdom, ⁵Center for Clinical Studies, Webster, TX, ⁶Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Janssen Research & Development, LLC, San Diego, CA, ⁸Janssen Scientific Affairs, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Innovaderm Research, Montreal, QC, Canada
Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
Abstract Number: 0360 • ACR Convergence 2024
What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study
Cécile Gaujoux-Viala¹, Emmanuelle Dernis², Eric Senbel³ and René-Marc Flipo⁴, ¹CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³Cabinet de Rhumatologie, Marseille, France, ⁴Hôpital Roger Salengro, France, Lille, France
Background/Purpose: Treatment adherence is a major challenge in chronic inflammatory rheumatic diseases, particularly rheumatoid arthritis (RA), with adherence rates ranging from 30 to 80%. Given…
Abstract Number: 0347 • ACR Convergence 2024
Dermato-polymyositis Mortality in U.S. Population: Declining Cancer and Cardiovascular Diseases Among the Leading Underlying Causes of Death over Two Decades
Elizabeth Matz¹ and Ram Singh², ¹UCLA David Geffen School of Medicine, Los Angeles, ²UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Dermatomyositis and polymyositis (DM/PM) are chronic inflammatory muscle diseases that may cause premature death due to progressive muscle weakness, lung disease, and disease and…
Abstract Number: 0248 • ACR Convergence 2024
Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study
Nadia Aikawa¹, Ana Cristina Medeiros-Ribeiro², Sandra Pasoto³, Leonard Kupa³, Luciana Seguro⁴, ANA PAULA ASSAD³, Eduardo Borba³, Carla Goncalves Schahin Saad⁴, Emily Figueiredo Neves Yuki³, Danieli Andrade⁵, Andrea Shimabuco⁴, Karina Bonfiglioli³, Diogo Domiciano³, Julio Moraes³, Samuel Shinjo⁴, Percival Sampaio-Barros⁴, Henrique Giardini³, Joao de Oliveira³, Isabele Antonelli³, Renata Pinheiro³, Thais Bonini³, Marta Lopes⁶, Clovis Silva⁷ and Eloisa Bonfa³, ¹Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵University of São Paulo, São Paulo, SP, Brazil, ⁶Infectious Disease Department, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are at high risk of herpes zoster (HZ) due to their condition and treatment. The new recombinant vaccine…
Abstract Number: 0343 • ACR Convergence 2024
An Interlaboratory Variability Study of Detection Methods for Myositis-Specific and Myositis-Associated Autoantibodies in Sera from Patients with Idiopathic Inflammatory Myopathies
Georgina Harvey¹, Idil Ashur², Xavier Bossuyt³, Martin Bluethner⁴, Anna Brusch⁵, Chris Bundell⁵, hector Chinoy⁶, Claire Coeshott⁷, Charmaine Donald², Juliet Dunphy⁸, Marvin Fritzler⁹, Adrian Heaps², marie Hudson¹⁰, Masataka Kuwana¹¹, Océane Landon-Cardinal¹², Hui Lu¹, FIONNUALA MCMORROW¹, Marie Mayrhofer⁴, Alain Meyer¹³, Birthe Michiels³, Benoit Nespola¹⁴, Susan O'Loughlin¹⁵, Ivana Putova¹⁶, Johan Rönnelid¹⁷, Ross Sadler¹⁸, Maria Teresa Sanz-Martinez¹⁹, Paul Sciore²⁰, Albert Selva-O’Callaghan²¹, Helena Storfors²², Ernesto Trallero-Araguás²³, Yves Troyanov¹², Jade Tyson², Jiří Vencovský²⁴, Akira Yoshida²⁵ and Sarah Tansley¹, ¹University of Bath, Bath, United Kingdom, ²Severn Pathology, North Bristol NHS Trust, Bristol, United Kingdom, ³University Hospitals Leuven, Leuven, Belgium, ⁴MVZ Labor PD Dr. Volkmann und Kollegen GbR, Karlsruhe, Germany, ⁵Department of Clinical Immunology, PathWest Laboratory Medicine, Perth, Western Australia, Australia, ⁶The University of Manchester, Manchester, United Kingdom, ⁷Advanced Diagnostics Laboratories National Jewish Health, Denver, CO, ⁸Royal United Hospital Bath NHS Foundation Trust, Bath, United Kingdom, ⁹Mitogen Diagnostics Corp, Calgary, AB, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹²Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ¹³UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ¹⁴Laboratoire d’immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹⁵Greater Manchester Immunology Service, Manchester, England, United Kingdom, ¹⁶Institute of Rheumatology, Prague, Czech Republic, ¹⁷Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ¹⁸Laboratory of Immunology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England, United Kingdom, ¹⁹Immunology Division, Vall d'Hebron Hospital, Barcelona, Spain, ²⁰Mitogen Diagnostics Corp., Calgary, ²¹Internal Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, ²²Department of Clinical Immunology and Transfusion Medicine, Uppsala University Hospital, Uppsala, Sweden, ²³Rheumatology Departament, Vall d'Hebron Hospital, Barcelona, Spain, ²⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²⁵Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan
Background/Purpose: In idiopathic inflammatory myopathy (IIM) spectrum diseases, myositis-specific and myositis-associated autoantibodies (MSAs/MAAs) are key markers of disease subtype and prognosis and are considered routine…
Abstract Number: 0345 • ACR Convergence 2024
Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh’s Myositis Registry
Chester Oddis¹, Jan Feifel², Dana Ascherman³, Diane Carol Koontz⁴, Caroline Foch², Luisa Henkel⁵, Jeffrey M. Muir⁶, Deborah Denis⁷ and Rohit Aggarwal⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²the healthcare business of Merck KGaA, Darmstadt, Germany, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany, Weiterstadt, Germany, ⁶Cytel, Inc., Toronto, Canada, ⁷EMD Serono, Rockland, MA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Glucocorticoids (GC) in high doses remain the first-line treatment for dermatomyositis (DM). One or more immunosuppressive agents are given concomitantly as steroid-sparing agents to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].